What genetic mutations are commonly found in MDS

Common Genetic Mutations in MDS

Myelodysplastic syndromes (MDS) involve mutations in blood-forming cells. Understanding these mutations helps doctors assess your disease and guide treatment decisions. According to the NCCN Guidelines for Myelodysplastic Syndromes, here are the most frequently found mutations:

Most Common Mutations

SF3B1 (20-30% of patients)

• This mutation affects how cells process genetic instructions
• Strongly associated with ring sideroblasts (abnormal iron accumulation in red blood cell precursors)
• Generally indicates a more favorable prognosis compared to other mutations

TET2 (20-25% of patients)

• Often found in patients with normal karyotypes (normal chromosome appearance)
• More frequent in a specific MDS subtype called CMML (chronic myelomonocytic leukemia)
• Can predict better response to hypomethylating agents (a type of chemotherapy)

ASXL1 (15-25% of patients)

• Independently associated with poor prognosis
• More common in CMML
• Suggests more aggressive disease behavior

DNMT3A (12-18% of patients)

• More frequently seen in AML (acute myeloid leukemia)
• Can occur in certain patterns that doctors monitor closely

SRSF2, U2AF1, and ZRSR2 (10-15% combined)

• These affect the spliceosome (the machinery that processes genetic instructions)
• Associated with poor prognosis, particularly U2AF1 and ZRSR2
• More common in CMML

Other Important Mutations

TP53 (8-12% of patients)

• Independently associated with poor prognosis
• More frequent when complex karyotypes are present
• May predict resistance to lenalidomide (a targeted therapy)

RUNX1 (10-15% of patients)

• Independently associated with poor prognosis
• Affects normal blood cell development

EZH2 (5-10% of patients)

• Independently associated with poor prognosis
• More common in CMML

Less Common but Important Mutations:

• TP53 multi (multiple TP53 mutations) - poor prognosis
• BCOR, BCORL1 - associated with poor prognosis
• GATA2, ETV6, WT1 - associated with poor prognosis
• SETBP1 - associated with disease progression
• IDH1 and IDH2 - more frequent in AML; associated with poor prognosis

Why Mutations Matter for Your Care

According to NCCN Guidelines, doctors use mutation information to:

1. Confirm MDS diagnosis - Mutations help establish that you have MDS rather than another condition

2. Assess prognosis - Certain mutations indicate more aggressive disease

3. Guide treatment - Specific mutations open up targeted therapy options:

   • IDH1 mutations → Ivosidenib may be considered
   • IDH2 mutations → Enasidenib may be considered
   • TET2 mutations → Better response to hypomethylating agents (azacitidine or decitabine)

4. Predict treatment response - For example, TP53 mutations may predict resistance to lenalidomide

Important Context

The NCCN Guidelines emphasize that:

• No single mutation diagnoses MDS - Your complete clinical picture (blood counts, bone marrow appearance, symptoms) matters
• Absence of mutations doesn't exclude MDS - You can have MDS without detectable mutations
• Some mutations occur in aging - Finding a mutation doesn't automatically mean disease; context is essential
• Multiple mutations matter - Having several mutations may indicate more aggressive disease than a single mutation

Questions to Ask Your Doctor

1. Which mutations do I have, and what do they mean for my specific situation?
2. How do my mutations affect my prognosis and treatment options?
3. Will my mutations be monitored over time, and how often?
4. Do any of my mutations make me eligible for targeted therapies?
5. How do my mutations compare to the typical mutation patterns in MDS?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.